文献速递肿瘤 PET/CT

PET/CT影像组学在乳腺癌中新辅助化疗病理反应预测中的价值

PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-03-26

结果显示各模型AUC为0.70至0.73,所有模型一致认为肿瘤分子亚型是主要预测因子,HER2阳性及三阴性亚型较luminal亚型更可能获得pCR。

要点

  • PET影像组学特征构建的模型可预测局部晚期乳腺癌新辅助化疗的pCR,AUC为0.70至0.73。
  • 所有模型一致认为肿瘤分子亚型是pCR的主要预测因子。
  • HER2阳性及三阴性亚型较luminal亚型更可能获得pCR。

核心结论

  • PET影像组学特征可作为局部晚期乳腺癌患者新辅助化疗后pCR的潜在预测指标。
  • HER2阳性及三阴性亚型患者较luminal亚型更可能获得pCR。

研究设计与样本

  • 对PET图像原发灶进行勾画,使用LIFEx软件提取一阶、二阶及高阶影像特征。
  • 采用单变量和多变量logistic回归及lasso回归,在完整信息数据集和插补数据集上构建多个模型。

主要发现

  • 所有模型均可预测pCR,AUC范围为0.70至0.73。
  • 所有模型一致认为肿瘤分子亚型是主要终点的主要预测因子。

关键数值与推荐

  • pCR定义为新辅助化疗后的病理完全缓解。
  • 模型预测pCR的AUC范围为0.70至0.73。
  • 亚型2(HER2阳性)和亚型3(三阴性)患者较亚型1(luminal)更可能获得pCR。

临床怎么用

  • 治疗前18F-FDG PET/CT影像组学特征可辅助预测局部晚期乳腺癌新辅助化疗的pCR。
  • 结合肿瘤分子亚型(HER2阳性、三阴性)可进一步提示pCR可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the role of radiomics parameters in predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer. METHODS: Seventy-nine patients who had undergone pretreatment staging 18F-FDG PET/CT and treatment with NAC between January 2010 and January 2018 were included in the study. Primary lesions on PET images were delineated, and extraction of first-, second-, and higher-order imaging features was performed using LIFEx software. The relationship between these parameters and pCR to NAC was analyzed by multiple logistic regression models. RESULTS: Nineteen patients (24%) had pCR to NAC. Different models were generated on complete information and imputed datasets, using univariable and multivariable logistic regression and least absolute shrinkage and selection operator (lasso) regression. All models could predict pCR to NAC, with area under the curve values ranging from 0.70 to 0.73. All models agreed that tumor molecular subtype is the primary predictor of the primary endpoint. CONCLUSIONS: Our models predicted that patients with subtype 2 and subtype 3 (HER2+ and triple negative, respectively) are more likely to have a pCR to NAC than those with subtype 1 (luminal). The association between PET imaging features and pCR suggested that PET imaging features could be considered as potential predictors of pCR in locally advanced breast cancer patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Antunovic L, De Sanctis R, Cozzi L, et al. PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2019. PMID: 30915523. doi:10.1007/s00259-019-04313-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。